302 related articles for article (PubMed ID: 28399108)
1. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
[TBL] [Abstract][Full Text] [Related]
2. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to cabazitaxel.
Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
[TBL] [Abstract][Full Text] [Related]
4. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
5. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
Cassinelli G; Supino R; Perego P; Polizzi D; Lanzi C; Pratesi G; Zunino F
Int J Cancer; 2001 Jun; 92(5):738-47. PubMed ID: 11340581
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
Giannakakou P; Sackett DL; Kang YK; Zhan Z; Buters JT; Fojo T; Poruchynsky MS
J Biol Chem; 1997 Jul; 272(27):17118-25. PubMed ID: 9202030
[TBL] [Abstract][Full Text] [Related]
8. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
9. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
[TBL] [Abstract][Full Text] [Related]
10. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
11. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Sprowl JA; Reed K; Armstrong SR; Lanner C; Guo B; Kalatskaya I; Stein L; Hembruff SL; Tam A; Parissenti AM
Breast Cancer Res; 2012 Jan; 14(1):R2. PubMed ID: 22225778
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
Halder J; Landen CN; Lutgendorf SK; Li Y; Jennings NB; Fan D; Nelkin GM; Schmandt R; Schaller MD; Sood AK
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8829-36. PubMed ID: 16361572
[TBL] [Abstract][Full Text] [Related]
14. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.
Poruchynsky MS; Giannakakou P; Ward Y; Bulinski JC; Telford WG; Robey RW; Fojo T
Biochem Pharmacol; 2001 Dec; 62(11):1469-80. PubMed ID: 11728383
[TBL] [Abstract][Full Text] [Related]
15. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
16. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
18. β-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells.
Zou B; Li QQ; Zhao J; Li JM; Cuff CF; Reed E
Anticancer Res; 2013 Mar; 33(3):929-40. PubMed ID: 23482764
[TBL] [Abstract][Full Text] [Related]
19. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
[TBL] [Abstract][Full Text] [Related]
20. MiR-200c and HuR in ovarian cancer.
Prislei S; Martinelli E; Mariani M; Raspaglio G; Sieber S; Ferrandina G; Shahabi S; Scambia G; Ferlini C
BMC Cancer; 2013 Feb; 13():72. PubMed ID: 23394580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
